Stoke Therapeutics 将来の成長

Future 基準チェック /26

Stoke Therapeutics利益と収益がそれぞれ年間35%と35.7%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-117.8% 34.3%なると予測されています。

主要情報

35.0%

収益成長率

34.35%

EPS成長率

Biotechs 収益成長	22.8%
収益成長率	35.7%
将来の株主資本利益率	-117.80%
アナリストカバレッジ	Good
最終更新日	20 Mar 2026

今後の成長に関する最新情報

Recent updates

Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts

Jan 12

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry

Dec 05

Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating

Dec 04

Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%

Oct 09

Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified

Aug 25

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate

Aug 15

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry

May 20

Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be

Apr 16

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Apr 05

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Feb 26

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Feb 16

Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts

Nov 08

Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts

Nov 06

It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope

May 30

業績と収益の成長予測

NasdaqGS:STOK - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	122	-144	-64	-108	9
12/31/2027	49	-214	-200	-201	10
12/31/2026	27	-215	-210	-182	12
12/31/2025	184	-7	45	46	N/A
9/30/2025	206	41	52	53	N/A
6/30/2025	200	52	61	62	N/A
3/31/2025	191	50	69	70	N/A
12/31/2024	37	-89	-87	-87	N/A
9/30/2024	17	-105	-85	-84	N/A
6/30/2024	15	-104	-81	-80	N/A
3/31/2024	8	-109	-86	-84	N/A
12/31/2023	9	-105	-83	-81	N/A
9/30/2023	9	-103	-85	-83	N/A
6/30/2023	9	-105	-91	-88	N/A
3/31/2023	15	-99	-89	-86	N/A
12/31/2022	12	-101	-36	-32	N/A
9/30/2022	9	-100	-30	-26	N/A
6/30/2022	6	-96	-20	-18	N/A
3/31/2022	3	-94	-16	-14	N/A
12/31/2021	N/A	-86	-68	-67	N/A
9/30/2021	N/A	-76	-63	-62	N/A
6/30/2021	N/A	-67	-59	-58	N/A
3/31/2021	N/A	-58	-52	-52	N/A
12/31/2020	N/A	-52	-43	-42	N/A
9/30/2020	N/A	-48	-43	-41	N/A
6/30/2020	N/A	-43	-41	-39	N/A
3/31/2020	N/A	-38	-37	-35	N/A
12/31/2019	N/A	-32	-33	-31	N/A
9/30/2019	N/A	-26	N/A	-24	N/A
6/30/2019	N/A	-21	N/A	-19	N/A
3/31/2019	N/A	-16	N/A	-16	N/A
12/31/2018	N/A	-13	N/A	-11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: STOK今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: STOK今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: STOK今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: STOKの収益 ( 35.7% ) US市場 ( 10.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: STOKの収益 ( 35.7% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: STOK 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/04/12 08:05
終値	2026/04/10 00:00
収益	2025/12/31
年間収益	2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Stoke Therapeutics, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。21

アナリスト	機関
Gregory Harrison	BofA Global Research
Thomas Shrader	BTIG
Michelle Gilson	Canaccord Genuity

Stoke Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 8.2% to US$45.10

Consensus EPS estimates increase by 79%

Price target increased by 13% to US$41.89

Price target increased by 8.2% to US$39.63

Price target increased by 8.4% to US$37.13

Consensus EPS estimates increase by 10%

Recent updates

Stoke Therapeutics, Inc. Appoints Clare Kahn as Directors and to Serve on Nominating and Corporate Governance Committee and as Chairperson of the Research and Development Committee of the Board, Effective April 3, 2026

Chief Medical Officer recently sold US$413k worth of stock

Price target increased by 8.2% to US$45.10

Full year 2025 earnings: EPS and revenues miss analyst expectations

Stoke Therapeutics and Biogen Announce Data Publication for Zorevunersen in Dravet Syndrome

Consensus EPS estimates increase by 79%

Stoke Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Study of STK-002

Price target increased by 13% to US$41.89

Price target increased by 8.2% to US$39.63

Investor sentiment deteriorates as stock falls 16%

Price target increased by 8.4% to US$37.13

Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts

Stoke Therapeutics, Inc. Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Consensus EPS estimates increase by 10%

Price target increased by 13% to US$36.63

Price target increased by 8.3% to US$34.25

Advisor & Director exercised options and sold US$467k worth of stock

Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry

Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating

Investor sentiment improves as stock rises 15%

Stoke Therapeutics, Inc. and Biogen Inc. Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome

Price target increased by 9.4% to US$30.89

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorates as stock falls 21%

Stoke Therapeutics, Inc. Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)

New minor risk - Share price stability

Price target increased by 11% to US$27.00

Stoke Therapeutics, Inc. and Biogen Inc. Present New Data at the 54th Child Neurology Society Annual Meeting That Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%

Price target increased by 10% to US$25.56

Investor sentiment improves as stock rises 16%

Stoke Therapeutics, Inc. Appoints Ian F. Smith as Chief Executive Officer

Advisor & Director notifies of intention to sell stock

Investor sentiment improves as stock rises 22%

Stoke Therapeutics, Inc. and Biogen Inc. Present Data At the 36Th International Epilepsy Congress That Support the Potential for Zorevunersen to Be the First Disease-Modifying Medicine for Dravet Syndrome

Advisor & Director notifies of intention to sell stock

Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified

Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

Advisor & Director recently sold US$221k worth of stock

Investor sentiment improves as stock rises 37%

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate

Now 23% overvalued after recent price rise

Stoke Therapeutics, Inc. and Biogen Inc. Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, A Potential Disease-Modifying Treatment for Dravet Syndrome

Consensus EPS estimates increase by 14%

Investor sentiment improves as stock rises 15%

Stoke Therapeutics, Inc. and Biogen Inc. Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet Syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

Consensus EPS estimates fall by 26%

Investor sentiment improves as stock rises 19%

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Stoke Therapeutics, Inc., Annual General Meeting, Jun 03, 2025

Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be

Consensus revenue estimates decrease by 11%

Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Consensus revenue estimates increase by 70%

Advisor & Director recently sold US$164k worth of stock

Stoke Therapeutics, Inc. Announces CEO Changes, Effective March 19, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Stoke Therapeutics, Inc. Appoints Arthur Tzianabos as Interim Executive Chairman

We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely

Price target increased by 7.8% to US$24.25

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

New minor risk - Share price stability

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate A Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

New major risk - Revenue and earnings growth

Chief Medical Officer recently sold US$178k worth of stock

Stoke Therapeutics, Inc. Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Chief Medical Officer exercised options and sold US$115k worth of stock